Ocugen Stock-Based Compensation Growth & History (OCGN)
Ocugen's stock-based compensation was $7.7M for fiscal 2025.
View full Ocugen company overviewOcugen annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.7M | $280,000 | +3.77% |
| 2024 | 2024-12-31 | $7.4M | −$1.8M | −19.42% |
| 2023 | 2023-12-31 | $9.2M | −$1.3M | −12.56% |
| 2022 | 2022-12-31 | $10.5M | $3.6M | +51.49% |
| 2021 | 2021-12-31 | $7.0M | $6.3M | +954.24% |
| 2020 | 2020-12-31 | $660,000 | −$224,000 | −25.34% |
| 2019 | 2019-12-31 | $884,000 | −$741,000 | −45.60% |
| 2018 | 2018-12-31 | $1.6M | $52,000 | +3.31% |
| 2017 | 2017-12-31 | $1.6M | $25,000 | +1.61% |
| 2016 | 2016-12-31 | $1.5M | $320,000 | +26.06% |
| 2015 | 2015-12-31 | $1.2M | $681,000 | +124.50% |
| 2014 | 2014-12-31 | $547,000 | — | — |
Ocugen quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | −$12,000 | −0.65% |
| Q1 2026 | 2026-03-31 | $3.4M | $1.5M | +80.27% |
| Q4 2025 | 2025-12-31 | $2.0M | $125,000 | +6.66% |
| Q3 2025 | 2025-09-30 | $2.0M | $84,000 | +4.44% |
| Q2 2025 | 2025-06-30 | $1.8M | −$53,000 | −2.79% |
| Q1 2025 | 2025-03-31 | $1.9M | $124,000 | +7.04% |
| Q4 2024 | 2024-12-31 | $1.9M | $154,000 | +8.94% |
| Q3 2024 | 2024-09-30 | $1.9M | −$282,000 | −12.97% |
| Q2 2024 | 2024-06-30 | $1.9M | −$734,000 | −27.89% |
| Q1 2024 | 2024-03-31 | $1.8M | −$928,000 | −34.51% |
| Q4 2023 | 2023-12-31 | $1.7M | −$946,000 | −35.46% |
| Q3 2023 | 2023-09-30 | $2.2M | −$321,000 | −12.87% |
| Q2 2023 | 2023-06-30 | $2.6M | $553,000 | +26.60% |
| Q1 2023 | 2023-03-31 | $2.7M | −$610,000 | −18.49% |
| Q4 2022 | 2022-12-31 | $2.7M | −$15,000 | −0.56% |
| Q3 2022 | 2022-09-30 | $2.5M | $1.1M | +85.23% |
| Q2 2022 | 2022-06-30 | $2.1M | −$16,000 | −0.76% |
| Q1 2022 | 2022-03-31 | $3.3M | $2.5M | +296.04% |
| Q4 2021 | 2021-12-31 | $2.7M | $2.5M | +1546.01% |
| Q3 2021 | 2021-09-30 | $1.3M | $1.2M | +969.05% |
| Q2 2021 | 2021-06-30 | $2.1M | $1.9M | +1306.04% |
| Q1 2021 | 2021-03-31 | $833,000 | $611,000 | +275.23% |
| Q4 2020 | 2020-12-31 | $163,000 | −$383,995 | −70.20% |
| Q3 2020 | 2020-09-30 | $126,000 | −$67,005 | −34.72% |
| Q2 2020 | 2020-06-30 | $149,000 | $112,000 | +302.70% |
| Q1 2020 | 2020-03-31 | $222,000 | $115,000 | +107.48% |
| Q4 2019 | 2019-12-31 | $546,995 | $170,995 | +45.48% |
| Q3 2019 | 2019-09-30 | $193,005 | −$245,995 | −56.04% |
| Q2 2019 | 2019-06-30 | $37,000 | −$370,000 | −90.91% |
| Q1 2019 | 2019-03-31 | $107,000 | −$296,000 | −73.45% |
| Q4 2018 | 2018-12-31 | $376,000 | $36,000 | +10.59% |
| Q3 2018 | 2018-09-30 | $439,000 | $70,000 | +18.97% |
| Q2 2018 | 2018-06-30 | $407,000 | $35,000 | +9.41% |
| Q1 2018 | 2018-03-31 | $403,000 | −$89,000 | −18.09% |
| Q4 2017 | 2017-12-31 | $340,000 | −$128,000 | −27.35% |
| Q3 2017 | 2017-09-30 | $369,000 | −$64,000 | −14.78% |
| Q2 2017 | 2017-06-30 | $372,000 | $36,000 | +10.71% |
| Q1 2017 | 2017-03-31 | $492,000 | $181,000 | +58.20% |
| Q4 2016 | 2016-12-31 | $468,000 | $94,000 | +25.13% |
| Q3 2016 | 2016-09-30 | $433,000 | $71,000 | +19.61% |
| Q2 2016 | 2016-06-30 | $336,000 | $79,000 | +30.74% |
| Q1 2016 | 2016-03-31 | $311,000 | $76,000 | +32.34% |
| Q4 2015 | 2015-12-31 | $374,000 | $183,000 | +95.81% |
| Q3 2015 | 2015-09-30 | $362,000 | $194,000 | +115.48% |
| Q2 2015 | 2015-06-30 | $257,000 | $145,000 | +129.46% |
| Q1 2015 | 2015-03-31 | $235,000 | $159,000 | +209.21% |
| Q4 2014 | 2014-12-31 | $191,000 | — | — |
| Q3 2014 | 2014-09-30 | $168,000 | — | — |
| Q2 2014 | 2014-06-30 | $112,000 | — | — |
| Q1 2014 | 2014-03-31 | $76,000 | — | — |
Ocugen stock-based compensation trends
Over the last five fiscal years, Ocugen's stock-based compensation increased from $660,000 to $7.7M, a change of $7.0M. The latest reported quarter, Q2 2026, shows $1.8M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ocugen source filings ↗